(I) The Healthcare Reform Programs in China prompt the new turning points of the medical device industry.
(II) The Health Reform Program in the United States would mean a golden niche to Taiwans manufacturers with their expertise in high quality but competitive pricing.
(III) The government in Taiwan is to ease up incentives toward Class III high risk medical devices under the Biotech and New Pharmaceutical Development Act